Clinical research progress of soluble guanylate cyclase stimulator Vericiguat in heart failure
-
摘要: 心力衰竭(heart failure，HF)是心血管疾病发展的终末结局和心血管疾病患者最主要的死亡原因。近年来，随着进一步的研究，HF的治疗正在不断完善，然而HF患者的高住院率和高病死率在目前依旧是一大难题，其生活质量和预后仍处于较低水平。而维利西呱作为一种可溶性鸟苷酸环化酶激动剂，以其独特的作用机制和良好的安全性、耐受性为HF治疗提供了新思路，可谓潜力巨大。本文就维利西呱的作用通路、安全性、耐受性方面以及目前相关临床研究进展进行综述。
-
关键词:
- 维利西呱 /
- 心力衰竭 /
- 可溶性鸟苷酸环化酶激动剂 /
- 一氧化氮-可溶性鸟苷酸环化酶-环磷酸鸟苷信号途径
Abstract: Heart failure(HF) is the final outcome of cardiovascular disease development and the main cause of death in patients with cardiovascular disease. In recent years, with further in-depth research, the treatment of HF is constantly improving. However, the high hospitalization rate and high mortality rate of HF patients are still a major problem, and their quality of life and prognosis are still at a low level. As a soluble guanylate cyclase stimulator, vericiguat provides new ideas for the treatment of HF with its unique mechanism of action, good safety and tolerability, which has great potential. In this paper, we reviewed the pathways, safety and tolerability of vericiguat and the current clinical research progress. -
-
[1] Murphy SP, Ibrahim NE, Januzzi JJ. Heart failure with reduced ejection fraction: a review[J]. JAMA, 2020, 324(5): 488-504. doi: 10.1001/jama.2020.10262
[2] Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet, 2017, 390(10100): 1211-1259.
[3] Wang H, Chai K, Du M, et al. Prevalence and incidence of heart failure among urban patients in china: a national population-based analysis[J]. Circ Heart Fail, 2021, 14(10): e8406.
[4] 王华, 刘宇佳, 杨杰孚. 心力衰竭流行病学[J]. 临床心血管病杂志, 2023, 39(4): 243-247. https://lcxxg.whuhzzs.com/article/doi/10.13201/j.issn.1001-1439.2023.04.001
[5] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2022, 145(18): e876-e894.
[6] 葛均波, 霍勇, 杨杰孚, 等. 慢性心力衰竭"新四联"药物治疗临床决策路径专家共识[J]. 中国循环杂志, 2022, 37(8): 769-781. doi: 10.3969/j.issn.1000-3614.2022.08.003
[7] Breitenstein S, Roessig L, Sandner P, et al. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure[J]. Handb Exp Pharmacol, 2017, 243: 225-247.
[8] Shattuck Lecture MF. Nitric oxide and cyclic GMP in cell signaling and drug development[J]. N Engl J Med, 2006, 355(19): 2003-2011. doi: 10.1056/NEJMsa063904
[9] Gheorghiade M, Marti CN, Sabbah HN, et al. Soluble guanylate cyclase: a potential therapeutic target for heart failure[J]. Heart Fail Rev, 2013, 18(2): 123-134. doi: 10.1007/s10741-012-9323-1
[10] Sciatti E, Dallapellegrina L, Metra M, et al. New drugs for the treatment of chronic heart failure with a reduced ejection fraction: What the future may hold[J]. J Cardiovasc Med(Hagerstown), 2019, 20(10): 650-659. doi: 10.2459/JCM.0000000000000850
[11] 李柏红, 施恒荷, 刘斌. 新型抗心力衰竭药物的研究进展[J]. 中国医药, 2021, 16(1): 142-144.
[12] 皮淑芳, 丁冉, 赵云, 等. 可溶性鸟苷酸环化酶激动剂维利西呱的研究进展[J]. 世界临床药物, 2021, 42(4): 237-240.
[13] Gheorghiade M, Greene SJ, Butler J, et al. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial[J]. JAMA, 2015, 314(21): 2251-2262. doi: 10.1001/jama.2015.15734
[14] Gonzalez-Juanatey JR, Anguita-Sanchez M, Bayes-Genis A, et al. Vericiguat in heart failure: From scientific evidence to clinical practice[J]. Rev ClinEsp(Barc), 2022, 222(6): 359-369.
[15] Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in Patients with Heart Failure and reduced ejection fraction[J]. N Engl J Med, 2020, 382(20): 1883-1893. doi: 10.1056/NEJMoa1915928
[16] Ezekowitz JA, O'Connor CM, Troughton RW, et al. N-Terminal Pro-B-Type Natriuretic Peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study[J]. JACC Heart Fail, 2020, 8(11): 931-939. doi: 10.1016/j.jchf.2020.08.008
[17] Senni M, Lopez-Sendon J, Cohen-Solal A, et al. Vericiguat and NT-proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial[J]. ESC Heart Fail, 2022, 9(6): 3791-3803. doi: 10.1002/ehf2.14050
[18] Boettcher M, Thomas D, Mueck W, et al. Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase Ⅰ studies in healthy subjects[J]. Eur J Clin Pharmacol, 2021, 77(4): 527-537. doi: 10.1007/s00228-020-03023-7
[19] 张班, 刘晓刚, 胡立群. 射血分数保留的心力衰竭研究新进展[J]. 临床心血管病杂志, 2022, 38(4): 271-275. https://lcxxg.whuhzzs.com/article/doi/10.13201/j.issn.1001-1439.2022.04.004
[20] Pieske B, Butler J, Filippatos G, et al. Rationale and design of the soluble guanylate Cyclase stimulator in heart failure studies(SOCRATES)[J]. Eur J Heart Fail, 2014, 16(9): 1026-1038. doi: 10.1002/ejhf.135
[21] Pieske B, Maggioni AP, Lam C, et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the soluble guanylate cyclase stimulator in heart failure patients with PRESERVED EF(SOCRATES-PRESERVED)study[J]. Eur Heart J, 2017, 38(15): 1119-1127. doi: 10.1093/eurheartj/ehw593
[22] Butler J, Lam C, Anstrom KJ, et al. Rationale and design of the VITALITY-HFpEF Trial[J]. Circ Heart Fail, 2019, 12(5): e5998.
[23] Ghali JK, Wikstrand J, Van Veldhuisen DJ, et al. The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF(MERIT-HF)[J]. J Card Fail, 2009, 15(4): 310-318. doi: 10.1016/j.cardfail.2008.11.003
[24] Anand IS, Bishu K, Rector TS, et al. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure[J]. Circulation, 2009, 120(16): 1577-1584. doi: 10.1161/CIRCULATIONAHA.109.853648
[25] Bowling CB, Sanders PW, Allman RM, et al. Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial[J]. Int J Cardiol, 2013, 167(1): 151-156. doi: 10.1016/j.ijcard.2011.12.056
[26] Follmann M, Ackerstaff J, Redlich G, et al. Discovery of the soluble guanylate cyclase stimulator vericiguat(BAY 1021189) for the treatment of chronic heart failure[J]. J Med Chem, 2017, 60(12): 5146-5161. doi: 10.1021/acs.jmedchem.7b00449
[27] Boettcher M, Gerisch M, Lobmeyer M, et al. Metabolism and pharmacokinetic drug-drug interaction profile of vericiguat, a soluble guanylate cyclase stimulator: results from preclinical and phase ihealthy volunteer studies[J]. Clin Pharmacokinet, 2020, 59(11): 1407-1418. doi: 10.1007/s40262-020-00895-x
[28] 陈晨, 刘怿晗, 罗敏, 等. 可溶性鸟苷酸环化酶激动剂维利西呱在心力衰竭领域的研究进展[J]. 中国医院药学杂志, 2022, 42(3): 333-337.
[29] Kassis-George H, Verlinden NJ, Fu S, et al. Vericiguat in heart failure with a reduced ejection fraction: patient selection and special considerations[J]. Ther Clin Risk Manag, 2022, 18: 315-322. doi: 10.2147/TCRM.S357422
[30] Cinza SS, Mazon RP, Iglesias AD, et al. Longer-term results of the cardiology e-consult program in patients with heart failure[J]. Rev Esp Cardiol(Engl Ed), 2022, 75(1): 93-95. doi: 10.1016/j.recesp.2021.06.011
[31] Armstrong PW, Roessig L, Patel MJ, et al. A Multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: The VICTORIA Trial[J]. JACC Heart Fail, 2018, 6(2): 96-104. doi: 10.1016/j.jchf.2017.08.013
[32] 陆军, 金杰妮, 王慧, 等. 可溶性鸟苷酸环化酶激动剂治疗慢性心力衰竭临床应用进展[J]. 浙江医学, 2021, 43(22): 2492-2496. doi: 10.12056/j.issn.1006-2785.2021.43.22.2021-1081
[33] Anker SD, Butler J, Filippatos GS, et al. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failureanda preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial[J]. Eur J Heart Fail, 2019, 21(10): 1279-1287. doi: 10.1002/ejhf.1596
[34] 刘平, 邱博, 吴惠珍. 维利西呱治疗心力衰竭的药理作用与临床评价[J]. 中国临床药理学与治疗学, 2022, 27(2): 212-218.
[35] Kansakar S, Guragain A, Verma D, et al. Soluble guanylate cyclase stimulators in heart failure[J]. Cureus, 2021, 13(9): e17781.
-
计量
- 文章访问数: 442
- PDF下载数: 32
- 施引文献: 0
下载: